EARNING RECAP

Johnson & Johnson

#JNJ 2019 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q1 adjusted $2.10 est. $2.04 $20.02B est. $19.61B +1.10% ($138.02 closing price) $140.70 $137.56 raises FY19 adjusted EPS view to $8.53-$8.63 from $8.50- $8.65; raises Fy19 revenue growth guidance to 2.5%- 3.5% from 2%- 3%
#JNJ 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adj EPS $1.74 vs $1.72 $20.2B vs $20.07B -4.26% $147.44 $141.62 Does not expect any generic compeition for Zytiga in 2018. Stock pop and sold off.
Q3 adj $1.90 Vs $1.80 estimate $19.70B vs $19.28B +3.43% closed at $140.79 $141.12 $137.06 Says sales performance was most pronounced in pharmaceutical segment
Q2 $1.83 Vs $1.79 $18.8B $18.5B +1.75% closed at $134.46 $134.95 $131.08 Guidance raises revenues: $75.8B from $75.40B
Q1 $1.83 Vs $1.77 $17.8B Vs 18.03B -3.10%. Closed at $121.82 $123.37 $120.95 CEO says 'confident' in achieving full year guidance. Stock gapped down, trade below 50sma 122.75.

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.